Madrigal Pharmaceuticals said on Wednesday it has entered into a licensing agreement worth up to $2 billion with China's CSPC Pharmaceutical Group to develop an oral GLP-1 drug for a serious form of ...

Thousands find weight loss relief on Zepbound. Now, they face a choice: Try a different medicine that may have adverse side effects or stop treatment.

IXJ offers global healthcare exposure, capturing demographic shifts and innovation trends beyond U.S.-centric ETFs. Read why ...

Though nerves abound for funders and founders in the industry, money continues to flow into startups, sometimes in ...

The record-setting Alexandria lab lease in San Diego showcases how biotech has few big tenants left to take empty spaces.

Two diabetes drugs could become more affordable for Maryland residents, following a study by the Prescription Drug ...

Danish drugmaker Novo Nordisk's stock was down nearly 20% in premarket trading Tuesday morning after the company cut its ...

Shares of Hims & Hers, which has clashed with Novo Nordisk over its sales of compounded glucagon-like peptide inhibitors, rose slightly in the wake of the report, and have more than doubled in value ...

Novo now expects 2025 sales growth of 8%-14% in local currencies, down from its previous 13-21% range. It also lowered its ...

One of the more popular stocks in the pharmaceutical sector of late got the cold shoulder from investors on Tuesday. Eli Lilly (NYSE: LLY) closed today's trading session down by almost 6% in value, ...

Novo Nordisk stock (NVO) (DK:NOVO.B) slumped 21.83% to fall to a new three-year low. It was the stock's worst daily loss since a 26.15% fall on Oct. 19, 1987. It's fallen 24.77% over the past two days ...

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...